What an Online Menopause Visit actually covers

An online menopause visit typically reviews symptoms using validated tools, screens personal and family history for hormone therapy risks, and discusses which labs may clarify the picture. Prescribing decisions weigh symptom burden, time since menopause, and contraindications — labs can inform the plan but are not always required for every patient.

A well-run online menopause visit is a structured conversation, not a lab-first checklist. The clinician's job is to characterize your symptoms, place you on the menopause timeline, screen for the handful of conditions that change the risk-benefit math, and then explain the options in plain terms. Labs can sharpen the picture — but for most women in the typical menopause age range, the diagnosis is clinical, and guidelines from The North American Menopause Society (NAMS) and ACOG are explicit about that.

Here is what a thorough visit actually covers, and why.

The symptom review, in plain English

The first half of the visit is almost entirely about what you are experiencing. Expect questions across four buckets:

• Vasomotor symptoms — hot flashes and night sweats, including how many per day, how disruptive, and whether they wake you.
• Genitourinary symptoms — vaginal dryness, pain with sex, urinary urgency, recurrent UTIs. These are often under-reported because patients assume they are untreatable. They are not.
• Sleep, mood, and cognition — early waking, new-onset anxiety, brain fog, irritability. These overlap with vasomotor symptoms but are tracked separately because they sometimes need their own approach.
• Menstrual pattern — cycle length, skipped cycles, flooding. This is what places you in perimenopause versus postmenopause.

Many clinicians use a validated tool like the Greene Climacteric Scale or the Menopause Rating Scale to quantify severity. That matters because it gives you a baseline to measure against in 8–12 weeks, rather than a vague "do I feel better?"

The history that changes the plan

This is the part that cannot be skipped on a telehealth visit, and a good clinician will spend real time here.

• Personal history of breast cancer, endometrial cancer, unprovoked VTE, stroke, coronary disease, active liver disease, or undiagnosed vaginal bleeding — any of these shift the conversation significantly, and some are absolute contraindications to systemic estrogen under Endocrine Society and NAMS guidance.
• Family history — particularly breast cancer and clotting disorders.
• Time since final menstrual period — the "timing hypothesis," supported by Women's Health Initiative follow-up analyses, suggests that benefit-to-risk is most favorable when systemic hormone therapy is started in women under 60 or within 10 years of menopause.
• Migraine with aura, blood pressure, BMI, smoking status, gallbladder history — all of these influence whether oral or transdermal estrogen is the better route, and whether a progestogen choice needs adjustment.
• Uterus present or not — this determines whether a progestogen is required alongside estrogen to protect the endometrium.

Labs: what actually helps

Here is where expectations often diverge from reality. For a woman in her late 40s or 50s with classic symptoms and a changing cycle, FSH and estradiol levels are not required to diagnose menopause — NAMS and ACOG both say so. Hormone levels fluctuate dramatically in perimenopause and a single draw can mislead.

That said, labs are genuinely useful in specific situations. If you choose to do bloodwork, the markers worth considering before a serious hormone therapy conversation often include:

• TSH — thyroid dysfunction mimics menopausal symptoms almost perfectly.
• CBC and ferritin — heavy perimenopausal bleeding is a common cause of iron deficiency, and fatigue blamed on "hormones" is sometimes anemia.
• Fasting lipids, glucose or A1c — baseline cardiometabolic context, especially before oral estrogen.
• FSH and estradiol — most useful when the diagnosis is actually in question: women under 45 with symptoms, women post-hysterectomy without ovaries removed, or ambiguous cases.
• Vitamin D, if clinically relevant.

The key pointLabs inform the plan; they rarely make the diagnosis. A thorough workup would typically pair symptom data with the handful of markers that actually change what gets prescribed.

How the prescription decision actually gets made

Assuming no contraindications and bothersome symptoms, the clinician is choosing across a few axes:

Systemic versus local therapy

If the dominant complaint is vaginal dryness or painful sex with no significant vasomotor symptoms, low-dose vaginal estrogen is often the first-line option. It is minimally absorbed and does not generally require a progestogen even in women with a uterus, per NAMS.

If vasomotor symptoms, sleep disruption, or mood are prominent, systemic therapy — estrogen with a progestogen if the uterus is intact — is the usual starting point in appropriate candidates.

Route of estrogen

Transdermal estrogen (patch, gel, spray) is often preferred over oral when VTE risk, migraine with aura, hypertriglyceridemia, or elevated BMI are in the picture, because it bypasses first-pass hepatic metabolism. Oral estrogen remains a reasonable choice for many women without those factors.

Progestogen choice

Micronized progesterone is commonly used alongside estrogen in women with a uterus and has a favorable profile in several comparative analyses, though synthetic progestins remain appropriate options depending on the clinical picture.

Non-hormonal options

For women who cannot or prefer not to take hormones, SSRIs/SNRIs (paroxetine has an FDA-approved indication for vasomotor symptoms), gabapentin, and the newer neurokinin-3 receptor antagonist fezolinetant are evidence-backed alternatives.

Doses are started low and titrated based on symptom response at 8–12 weeks, within the ranges published in NAMS and Endocrine Society guidance. There is no single "right" regimen — the right one is the lowest effective dose for your symptoms, in a formulation your risk profile tolerates.

What the follow-up looks like

The first prescription is a hypothesis, not a verdict.

A reasonable follow-up cadence is 8–12 weeks after starting therapy to reassess symptoms, side effects, bleeding patterns, and blood pressure, then annually once stable. Any new unscheduled bleeding on hormone therapy warrants evaluation. Mammography and cervical screening continue on standard schedules — telehealth does not replace those.

What an online visit cannot do

A video visit cannot perform a pelvic exam, a breast exam, or a transvaginal ultrasound. For most straightforward menopause care in a woman who is up to date on screening, that is not a barrier. But abnormal bleeding, a new breast finding, or pelvic pain belong in an in-person setting, and a good telehealth clinician will say so directly rather than work around it.

The honest version of what an online menopause visit offers: a structured, guideline-aligned conversation about your symptoms, your risk, and your options — with labs ordered when they actually change the plan, and a referral out when something needs hands-on evaluation. That is the standard of care, delivered through a screen.

References

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. Source
2. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. Source
3. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202-216. Source
4. Greene JG. Constructing a standard climacteric scale. Maturitas. 1998;29(1):25-31. Source
5. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.